Results 51 to 60 of about 15,943 (150)

Resolution of Levodopa/Dopa‐Decarboxylase Inhibitor—Associated Microscopic Colitis with Subcutaneous Foslevodopa/Foscarbidopa: A Case Series and Review of the Literature

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Microscopic colitis (MC) typically presents with chronic, non‐bloody watery diarrhea. Diagnosis requires endoscopy with colonic mucosal biopsies. The etiology is multifactorial, with several medications implicated, although only a few cases have been attributed to oral levodopa/dopa‐decarboxylase inhibitor (LDDCI) therapy.
Romana Hintner, Franziska Eberhardt, Manuela Kofler, Andreas Eigentler, Atbin Djamshidian, Florian Krismer, Anton Hittmair, Heinz Zoller, Valentina Ellinger, Beatrice Heim, Klaus Seppi   +10 more
wiley   +1 more source

Checkpoint inhibitors: What gastroenterologists need to know. [PDF]

, 2018
Checkpoint inhibitors are increasingly being used in clinical practice. They can cause various gastrointestinal, hepatic and pancreatic side effects. As these side effects can be serious, appropriate management is essential.
Ahmed, Monjur
core   +1 more source

αEβ7 Integrin Identifies Subsets of Pro-Inflammatory Colonic CD4+ T Lymphocytes in Ulcerative Colitis. [PDF]

, 2017
Background and Aims The αEβ7 integrin is crucial for retention of T lymphocytes at mucosal surfaces through its interaction with E-cadherin. Pathogenic or protective functions of these cells during human intestinal inflammation, such as ulcerative ...
Diehl, Lauri, Eastham-Anderson, Jeff, Egen, Jackson G, Gibbons, Deena, Hayday, Adrian, Irving, Peter, Jones, David E J, Keir, Mary E, Kirby, John A, Lamb, Christopher A, Long, Anna K, Mansfield, John C, O'Boyle, Graeme, O'Byrne, Sharon, Price, Maria B, Tew, Gaik W   +15 more
core   +1 more source

Nivolumab and immune-mediated colitis [PDF]

, 2019
Nivolumab is associated with a number of immune-regulated adverse events, including immune-mediated colitis and may present following the discontinuation of treatment.
Brennan, Paul, Carey, Frank, Groome, Maximillian, Walker, Heather, Walsh, Shaun   +4 more
core   +2 more sources

Frailty Is Associated With All‐Cause and Acute Hospitalisations During 18 Months Follow‐Up in Older Patients With Inflammatory Bowel Disease

Alimentary Pharmacology &Therapeutics, EarlyView.
The results of a geriatric assessment in older patients with IBD were associated with adverse health outcomes. Frailty, reflected by severe deficits in geriatric assessment, was independently associated with all‐cause and acute hospitalisations in older patients with IBD. ABSTRACT Background Guidelines recommend considering frailty in the management of
Anne B. Fons, Vera E. R. Asscher, Rogier J. L. Stuyt, A. Martine C. Baven‐Pronk, Sander van der Marel, Rutger J. Jacobs, Jeoffrey J. L. Haans, Andrea E. van der Meulen‐de Jong, Simon P. Mooijaart, Kees. J. Kalisvaart, P. W. Jeroen Maljaars   +10 more
wiley   +1 more source

Second Korean Guideline for the Management of Ulcerative Colitis [PDF]

, 2017
Ulcerative colitis (UC) is a chronic inflammatory bowel disease characterized by a relapsing and remitting course. The direct and indirect costs of the treatment of UC are high, and the quality of life of patients is reduced, especially during ...
���������
core   +1 more source

No Increased Risk of Infection Following a Protocol Change to Decrease Duration of Perioperative Antibiotic Prophylaxis in Liver Transplantation

Transplant Infectious Disease, EarlyView.
There was no increased rate of surgical site infection or bacteremia in liver transplant recipients following a decrease in perioperative antibiotic prophylaxis duration, with a change from 2.4% to 2.8% in patients hospitalized prior to transplant and 7.5% to 2.9% in other patients.
Hutton Brandon, Crystal M. Truax, Eduardo Rodriguez Zarate, Brandon J. Tritle, Hannah Imlay   +4 more
wiley   +1 more source

Sphingosine-1-phosphate receptor-1 (S1P1) is expressed by lymphocytes, dendritic cells, and endothelium and modulated during inflammatory bowel disease [PDF]

, 2016
The sphingosine-1-phosphate receptor-1 (S1P1) agonist ozanimod ameliorates ulcerative colitis, yet its mechanism of action is unknown. Here, we examine the cell subsets that express S1P1 in intestine using S1P1-eGFP mice, the regulation of S1P1 ...
AL Hart, AS Awad, BG Feagan, C Daniel, CB Collins, CB Collins, CN Skon, D Clark, D Kontoyiannis, DC Montrose, DJ Lenschow, E-h Behrens, EN McNamee, EN McNamee, F Scott, G Bamias, G Cinamon, G Gollmann, G Sarkisyan, G Sarkisyan, G Sarkisyan, H Rosen, H Zhang, J D Boyer, J Rivera-Nieves, J Song, JJ Liao, JW Choi, K Gaengel, KP MacDonald, L Gima, M Veny, MG Sanna, ML Allende, N Czeloth, OA Hatoum, P González-Cabrera, P Jedlicka, R Fujii, R Peach, RC Burns, S Eigenbrod, S Ghosh, S Mandala, S Spiegel, SM Cahalan, SR Schwab, T Karuppuchamy, T Mizushima, T Sanchez, V Brinkmann, William Sandborn, WJ Sandborn, Y Deguchi, Y Maeda, ZA Radi   +55 more
core   +1 more source

Vedolizumab Induces Remission in Two Cases of Ulcerative Colitis With Upper Gastrointestinal Involvement

DEN Open, Volume 6, Issue 1, April 2026.
ABSTRACT Ulcerative colitis (UC) predominantly affects the colon; upper gastrointestinal involvement (UGI) has been reported, but no established treatments exist. We report two cases of UC with concomitant UGI that showed positive responses to vedolizumab therapy.
Shinya Nakatani, Yuta Yamazaki, Kensuke Higuchi, Yumi Otoyama, Norihiro Suzuki, Kazuo Kikuchi, Takahisa Fujiwara, Atsushi Katagiri, Jyun Ohara, Hitoshi Yoshida   +9 more
wiley   +1 more source

Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. [PDF]

, 2017
Cancer immunotherapy has transformed the treatment of cancer. However, increasing use of immune-based therapies, including the widely used class of agents known as immune checkpoint inhibitors, has exposed a discrete group of immune-related adverse ...
Abdallah, K., Anderson, J., Andrews, S., Arrindell, D., Ballesteros, J., Bingham, C. O., Boyer, J., Brogdon, C., Chen, D., Chonzi, D., Cotarla, I., Cunha, R., Dadu, R., Davies, M., Dawson, M., Diab, A., Dicker, Adam, Eifler, L., Ernstoff, M. S., Ferguson, A., Ferlini, C., Frankel, S., Go, W., Gochett, C., Goldberg, J., Goncalves, P., Goswami, T., Gregory, N., Gulley, J. L., Hamad, L., Hayreh, V., Helie, N., Holmes, W., Hsu, J. Y., Ibrahim, R., Kaufman, H. L., Kim, S., Lacouture, M. E., Lambotte, O., Larocca, C., LeBoeuf, N. R., Lehman, K., Lenihan, D., Ley-Acosta, S., Luke, J., McClure, J., Michelon, E., Nakamura, M., Onofrei, C., Patel, K., Piperdi, B., Puzanov, I., Rasheed, Z., Reshef, D., Riemer, J., Robert, C., Sarkeshik, M., Saylors, A., Schreiber, J., Shafer-Weaver, K., Shannon, V., Sharfman, W., Sharma, R., Sharon, E., Sherry, R., Silk, A. W., Simonson, C., Skondra, D., Suarez-Almazor, M. E., Thomas, C., Thompson, J. A., Trehu, E., Tresnan, D., Turner, M., Wang, Y., Wariabharaj, D., Waxman, I., Wiley, K., Wood, L., Zhang, L., Zheng, P.   +80 more
core   +2 more sources